Search research articles
Contact Us
Filters
Showing results (41-50 of 69) with videos related to
Page
of 7
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 28, 2023
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers
Eduardo Gonzalez-Ochoa, Michael Milosevic, Bradley Corr, et al.
JAMA Oncology
|
April 14, 2022
Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled Trial
Eric Leung, Adam P Gladwish, Melanie Davidson, et al.
Journal of the National Cancer Institute
|
February 18, 2026
Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types
Bradley R Corr, Kara D Romano, Michael D Toboni, et al.
Plos One
|
October 31, 2019
Correction: Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma
Jennifer Teichman, Lorin Dodbiba, Henry Thai, et al.
Plos One
|
May 2, 2018
Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma
Jennifer Teichman, Lorin Dodbiba, Henry Thai, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
Ramez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
Ursula A Matulonis, Julie Lee, Brian Lasonde, et al.
The Lancet. Oncology
|
December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 30, 2018
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Aurélie Auguste, Catherine Genestie, Marco De Bruyn, et al.
Breast Cancer : Basic and Clinical Research
|
December 4, 2025
Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting
Karen Gambaro, Kahina Rachedi, Mark Basik, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 69) with videos related to
Sort By:
Page
of 7
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 28, 2023
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers
Eduardo Gonzalez-Ochoa, Michael Milosevic, Bradley Corr, et al.
JAMA Oncology
|
April 14, 2022
Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled Trial
Eric Leung, Adam P Gladwish, Melanie Davidson, et al.
Journal of the National Cancer Institute
|
February 18, 2026
Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types
Bradley R Corr, Kara D Romano, Michael D Toboni, et al.
Plos One
|
October 31, 2019
Correction: Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma
Jennifer Teichman, Lorin Dodbiba, Henry Thai, et al.
Plos One
|
May 2, 2018
Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma
Jennifer Teichman, Lorin Dodbiba, Henry Thai, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
Ramez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
Ursula A Matulonis, Julie Lee, Brian Lasonde, et al.
The Lancet. Oncology
|
December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 30, 2018
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Aurélie Auguste, Catherine Genestie, Marco De Bruyn, et al.
Breast Cancer : Basic and Clinical Research
|
December 4, 2025
Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting
Karen Gambaro, Kahina Rachedi, Mark Basik, et al.
Page
of 7